Interestingly, several studies proposed TLE3 as a potential marker of taxane responsiveness in the treatment of ovarian carcinoma and breast cancer [30, 31], but the most recent NCIC CTG MA.21 clinical trial repudiated TLE3 to be a valuable marker for taxane sensitivity in breast cancer treatment [32]. The gene discussed is TLE3; the disease is ovarian carcinoma.